Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer
暂无分享,去创建一个
S Detre | M. Dowsett | B. Sanghera | A. Makris | D. Miles | W. Wong | L. Sonoda | M. Beresford | M Dowsett | D. Woolf | S. P. Li | D K Woolf | M Beresford | S P Li | B Sanghera | W L Wong | L Sonoda | V Amin | M-L Ah-See | D Miles | A Makris | S. Detre | M. Ah-See | V. Amin
[1] R. Boellaard,et al. Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation in Patients With Advanced Non–Small Cell Lung Cancer Treated With Erlotinib , 2012, Clinical nuclear medicine.
[2] N. Satyamurthy,et al. RESEARCH A RTICLE Usefulness of 3 0 -(F-18)Fluoro-3 0 -deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy , 2006 .
[3] M. Bergström,et al. Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective. , 2009, Current pharmaceutical design.
[4] Mark Muzi,et al. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] Dimitris Visvikis,et al. Reproducibility of 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Tumor Volume Measurements , 2010, The Journal of Nuclear Medicine.
[6] H. Malcolm Hudson,et al. Accelerated image reconstruction using ordered subsets of projection data , 1994, IEEE Trans. Medical Imaging.
[7] Robert Jeraj,et al. Impact of Different Standardized Uptake Value Measures on PET-Based Quantification of Treatment Response , 2013, The Journal of Nuclear Medicine.
[8] A. Shields,et al. PET Imaging of Proliferation with Pyrimidines , 2013, The Journal of Nuclear Medicine.
[9] Mitch Dowsett,et al. Current and emerging biomarkers in breast cancer: prognosis and prediction. , 2010, Endocrine-related cancer.
[10] K. Gelmon,et al. Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.
[11] Eric O. Aboagye,et al. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[12] S. Shousha,et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. , 2005, Cancer research.
[13] R. Boellaard,et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Ronald Boellaard,et al. Effects of Image Characteristics on Performance of Tumor Delineation Methods: A Test–Retest Assessment , 2011, The Journal of Nuclear Medicine.
[15] R. Boellaard,et al. Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET , 2011, The Journal of Nuclear Medicine.
[16] Otto Muzik,et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.
[17] P. Marsden,et al. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. , 2012, European journal of cancer.
[18] Robin L. Jones,et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer , 2009, Breast Cancer Research and Treatment.
[19] O. Muzik,et al. Analysis and Reproducibility of 3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.
[20] M. Lubberink,et al. Validity of Simplified 3′-Deoxy-3′-[18F]Fluorothymidine Uptake Measures for Monitoring Response to Chemotherapy in Locally Advanced Breast Cancer , 2012, Molecular Imaging and Biology.
[21] Michael E Phelps,et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. , 2006, Chest.
[22] V. Pike,et al. An improved synthesis of 3′-DEOXY-3′-[18F]fluorothymidine ([18F]FLT) and the fate of the precursor, 2, 3′-anhydro-5′-O-(4, 4′-dimethoxytrityl)-thymidine , 2001 .
[23] F. Zeman,et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry , 2013, Breast Cancer Research and Treatment.
[24] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[25] R. Boellaard,et al. Reproducibility of quantitative 18 F-3 ′-deoxy-3 ′-fluorothymidine measurements using positron emission tomography , 2009 .
[26] Jack Cuzick,et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.
[27] Lale Kostakoglu,et al. Correlation of positron emission tomography standard uptake value and pathologic specimen size in cancer of the head and neck. , 2008, International journal of radiation oncology, biology, physics.
[28] R. Boellaard,et al. Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[29] A. Lammertsma,et al. [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study , 2008, British Journal of Cancer.
[30] Michael E. Phelps,et al. Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy , 2005, Molecular Imaging and Biology.
[31] Mitch Dowsett,et al. Proliferation marker Ki-67 in early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Torsten Mattfeldt,et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] H. Barthel,et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. , 2006, Cancer research.
[34] T. Lehnert,et al. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET , 2007, Leukemia & lymphoma.
[35] John L. Humm,et al. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[36] Markus Schwaiger,et al. Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine. , 2009, Methods.
[37] Gerald Reischl,et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[38] Shankar Vallabhajosula,et al. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. , 2007, Seminars in nuclear medicine.
[39] Takashi Nakajima,et al. Evaluation of thoracic tumors with 18F‐FMT and 18F‐FDG PET‐CT: A clinicopathological study , 2009, International journal of cancer.
[40] Fiona J Gilbert,et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Tushar C. Barot,et al. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[42] S. Shousha,et al. Biological basis of [11C]choline-positron emission tomography in patients with breast cancer: comparison with [18F]fluorothymidine positron emission tomography , 2011, Nuclear medicine communications.